Mahana Therapeutics has entered into a multi-million-dollar distribution and marketing partnership with the Consumer Health division of Bayer to commercialise digital therapeutics. Earlier this year, Bayer announced the launch of a new business unit focused on delivering new digitally enabled precision health products to market. Bayer is prioritising development of products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms.
"This historic partnership is among the first major investments ever made by a global life sciences company into the emerging marketplace for digital therapeutics. Mahana is proud to collaborate with the Bayer team who share our view that digital therapeutics are a critical part of the future of healthcare,” said Simon Levy, CEO of Mahana. “Through this agreement, we can further expand the availability of our innovative prescription digital therapeutics for patients and their caregivers around the world who seek effective treatment for chronic conditions.”
David Evendon-Challis, Head of R&D and Chief Scientific Officer for the Consumer Health division of Bayer added, “Digital therapeutics are a perfect addition to our portfolio of care and tap into new tech-savvy consumers looking for drug-free treatments as well as help eliminate gaps in care provision. We’re excited to partner with Mahana Therapeutics and enter the field of digital therapeutics in consumer health.”